ReviewArchives of disease in childhood2017
Challenges in reducing group B Streptococcus disease in African settings.
Review in Archives of disease in childhood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Prevalence of Group B Streptococcus Recto-Vaginal Colonization, Vertical Transmission, and Antibiotic Susceptibility Among Pregnant Women in Ethiopia: A Systematic Review and Meta-Analysis.Frontiers in public health · 2022Pooled it
- Current knowledge and future perspectives on management and prevention of group B streptococcus in neonates and young infants.Archives of disease in childhood. Fetal and neonatal edition · 2026Review
- Article
- Rapid Point-of-care Testing to Inform Intrapartum Treatment of Group BOpen forum infectious diseases · 2024Article
- Diagnosis and Management of Neonatal Bacterial Sepsis: Current Challenges and Future Perspectives.Tropical medicine and infectious disease · 2024Review
- Editorial: Women in infectious agents and disease: 2023.Frontiers in microbiology · 2024Article
- Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles.NPJ vaccines · 2023Article
- Immune responses against group BiScience · 2023Article
- The meningitis outbreak returns to Niger: Concern, efforts, challenges, and recommendations.Immunity, inflammation and disease · 2023Article
- Early-onset group B streptococcal disease in African countries and maternal vaccination strategies.Frontiers in public health · 2023Article
- Article
- Population genomics of Group B Streptococcus reveals the genetics of neonatal disease onset and meningeal invasion.Nature communications · 2022Article
- Vertical Transmission, Risk Factors, and Antimicrobial Resistance Patterns of Group BThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Article
- Vaginal microbiome topic modeling of laboring Ugandan women with and without fever.NPJ biofilms and microbiomes · 2021Article
- Whole genome sequence based capsular typing and antimicrobial resistance prediction of Group B streptococcal isolates from colonized pregnant women in Nigeria.BMC genomics · 2021Article
- Estimation of country-level incidence of early-onset invasive Group B Streptococcus disease in infants using Bayesian methods.PLoS computational biology · 2021Article
- Article
- Development and analytical validation of real-time PCR for the detection of Streptococcus agalactiae in pregnant women.BMC pregnancy and childbirth · 2020Article
- Vaccines for Perinatal and Congenital Infections-How Close Are We?Frontiers in pediatrics · 2020Review
- Maternal immunisation to improve the health of HIV-exposed infants.The Lancet. Infectious diseases · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Group B Streptococcus (GBS) is a leading cause of neonatal sepsis and meningitis in high-income settings and is associated with high rates of neonatal mortality and morbidity. There is now increasing evidence to suggest that there is a high GBS disease burden in resource-limited countries, and it is therefore critically important to identify suitable and practical preventive strategies. In Europe and North America, intrapartum antibiotic prophylaxis (IAP) has led to a dramatic reduction of early-onset GBS disease. However, the methods for identifying pregnant women who should receive IAP and how to reduce late-onset GBS disease are not without controversy and are challenging for most sub-Saharan African countries. GBS vaccines are approaching phase III trials but are still under development. This review aims to explore the current evidence related to strategies for reducing invasive GBS disease in an African setting, the development of a GBS vaccine and whether preventative measures against GBS disease can be practically implemented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.